bioRxiv Science⌕ Search

Biology subjects

Loureiro, P.

Publications and source records attributed to Loureiro, P..

2 recordsLinked to original sources

Late radiation-induced brain injury is associated with functional cerebrovascular impairment without structural vessel loss in mice

Background: Radiation-induced brain injury (RIBI) is a major and often irreversible complication of cranial radiotherapy, affecting up to 90% of long-term survivors. Although cerebrovascular damage is a leading mechanistic hypothesis, whether chronic resting hypoperfusion occurs independently of structural vessel loss remains unknown. The aim of this study was to comprehensively characterize cerebrovascular, structural, and behavioral outcomes in a murine model of late RIBI to determine the primary drivers of vascular dysfunction. Methods: Adult C57BL/6 mice underwent 12 Gy whole-brain irradiation and were assessed one year later using laser speckle contrast imaging (LSCI), 7T MRI, immunohistochemistry, and behavioral testing. Results: Irradiated mice exhibited reduced pial flow velocity and flow area by LSCI, indicative of upstream cerebrovascular dysfunction, while bulk cortical tissue perfusion was preserved. This pial hypoperfusion was accompanied by cerebral atrophy, decreased T2* relaxation time and tissue iron deposition consistent with chronic microhemorrhage across multiple brain regions by MRI, blood-brain barrier disruption reflected by reduced ZO-1 and VE-cadherin expression, and increased anxiety-like behavior. Strikingly, capillary density, pericyte coverage, astrocyte endfeet, and NeuN-positive neuronal nuclei were all preserved. Conclusion: These findings demonstrate that functional vascular impairment - not structural vessel or neuronal loss - drives hypoperfusion and blood-brain barrier disruption in late RIBI. This dissociation between vascular dysfunction and rarefaction reframes the pathophysiology of RIBI and identifies endothelial dysfunction as a tractable therapeutic target for intervention.

neuroscience↗

Use of an automated pyrosequencing technique for confirmation of Sickle Cell Disease

BackgroundThe diagnosis of sickle cell disease (SCD) is made by hemoglobin assays such as high-performance liquid chromatography (HPLC), isoelectric focusing and cellulose acetate or citrate agar electrophoresis. These assays are easy to perform and used in large-scale newborn screening in many countries. These tests however may not easily differentiate S{beta}0 thalassemia from SS or identify other hemoglobin variants, and in this case, hemoglobin (HBB) gene sequencing may be necessary.\n\nObjectivesTo develop a high throughput DNA based confirmatory assay for SCD and to detect mutations in the HBB gene.\n\nMethodsWe developed an automated pyrosequencing technique (PyS) based on QIAGEN technology (Hilden, Germany) to detect homozygous or heterozygous hemoglobin S mutations as well as hemoglobin C mutations. The technique was tested on 2,748 samples from patients enrolled in a multi-center SCD cohort in Brazil. Patients were previously tested using HPLC to diagnose SCD as part of routine clinical care. Any subjects with discrepant results between HPLC and PyS or with heterozygous hemoglobin S detected had Sanger sequencing of the HBB gene.\n\nResultsWe identified 168 samples with discrepant results between HPLC and PyS and 100 with concordant HPLC and PyS= heterozygous S, which would suggest S{beta}-thalassemia or other hemoglobin S variants. The PyS assay correctly identified 1906 (98.7%) of the 1930 HbSS and 628 (98.7%) of the 636 HbSC samples. Of the 179 remaining samples, PyS correctly indicated S heterozygosis in 165 (92.2%). Of the 165 heterozygous S samples confirmed by Sanger as consistent with S{beta} thalassemia genotype, 84 samples were classified as S{beta}0 thalassemia and 81 as S{beta}+ thalassemia. The most frequent beta thalassemia mutations of S{beta}0 and S{beta}+ were HBB: c.118C>T (Gln40Stop) and HBB c.92 + 6T> C, respectively.\n\nDiscussionThe PyS proved to be satisfactory for large-scale confirmatory testing of hemoglobin mutation. Moreover, with this study we were able to describe the most common {beta}+ and {beta}0 mutations in SCD patients with S{beta}-thalassemia in a large multi-institutional SCD cohort in Brazil.

molecular biology↗